INmune Bio to present preclinical data at 2023 AACR annual meeting on INB03

INmune Bio is presenting data on the use of INB03, a dominant-negative TNF inhibitor of soluble TNF in the treatment of high-risk MUC4 expressing HER2+ and triple negative breast cancer. Roxana Schillaci Ph.D. of Instituto de Biologia y Medicina Experimental in Buenos Aries, Argentina, will present data at the American Association of Cancer Research, AACR, Annual Meeting 2023 in Orlando Florida and has published a paper in Cancers as part of the Special Issue: Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. "Despite recent innovations in the treatment of HER2+ and triple-negative breast cancer, an unacceptably high number of women have resistant disease," said RJ Tesi M.D., CEO of INmune Bio. "MUC4 expression can be determined before treatment is initiated. Modifying the treatment to account for this new resistance mechanism may make is difference in the care of these woman."